{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:57:44Z","timestamp":1792292264018,"version":"4.4.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clcc.2021.09.006","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T22:36:09Z","timestamp":1631658969000},"page":"279-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-0218","authenticated-orcid":false,"given":"Marianne Gr\u00f8nlie","family":"Guren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sebag-Montefiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-0687","authenticated-orcid":false,"given":"Pierfrancesco","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-6144","authenticated-orcid":false,"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-3697","authenticated-orcid":false,"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen-Lise Garm","family":"Spindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2021.09.006_bib0001","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones","year":"2014","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.clcc.2021.09.006_bib0003","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41416-019-0689-x","article-title":"Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014)","volume":"122","author":"Sekhar","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0006","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0007","doi-asserted-by":"crossref","first-page":"852","DOI":"10.6004\/jnccn.2018.0060","article-title":"Anal carcinoma, version 2.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2021.09.006_bib0008","doi-asserted-by":"crossref","first-page":"O234","DOI":"10.1111\/codi.12553","article-title":"The rising incidence of anal cancer in England 1990-2010: a population-based study","volume":"16","author":"Wilkinson","year":"2014","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.clcc.2021.09.006_bib0009","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/CEJ.0000000000000163","article-title":"Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study","volume":"25","author":"Bouvier","year":"2016","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.clcc.2021.09.006_bib0010","first-page":"e96","article-title":"Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016","volume":"18","author":"Guren","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0011","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.2017.74.9291","article-title":"Anal cancer risk among people with HIV Infection in the United States","volume":"36","author":"Col\u00f3n-L\u00f3pez","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0013","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.25080","article-title":"Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005","volume":"127","author":"Sunesen","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0014","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2021.09.006_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.soc.2016.07.002","article-title":"Diagnosis and diagnostic imaging of anal canal cancer","volume":"26","author":"Ciombor","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.clcc.2021.09.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170370","article-title":"PET imaging in anal canal cancer: a systematic review and meta-analysis","volume":"90","author":"Mahmud","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0017","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","article-title":"The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis","volume":"22","author":"Jones","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0018","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.clcc.2021.09.006_bib0019","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0020","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0021","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0022","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal cancer trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0023","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0024","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2021.09.006_bib0025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK co-ordinating committee on cancer research","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2021.09.006_bib0026","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.radonc.2014.10.002","article-title":"Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines","volume":"113","author":"Leon","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0027","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/cncr.28045","article-title":"Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma","volume":"119","author":"Olivatto","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0028","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","article-title":"Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer","volume":"51","author":"Leon","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0029","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2015.02.008","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial","volume":"114","author":"Levy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0030","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0031","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2013a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0032","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","article-title":"Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort","volume":"101","author":"Jones","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0033","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0034","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0035","unstructured":"Muirhead R, Adams RA, Gilbert DC, et\u00a0al. National guidance for IMRT in anal cancer. Accessed 15.1.21 from http:\/\/analimrtguidance.co.uk\/."},{"key":"10.1016\/j.clcc.2021.09.006_bib0036","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.radonc.2020.05.018","article-title":"Patterns of inguinal lymph node metastases in anal canal cancer and recommendations for elective clinical target volume (CTV) delineation","volume":"149","author":"Garda","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0037","first-page":"39","article-title":"Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.clcc.2021.09.006_bib0038","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0039","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-018-1124-9","article-title":"Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study","volume":"13","author":"Franco","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.12.022","article-title":"UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes","volume":"128","author":"Gilbert","year":"2020","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clcc.2021.09.006_bib0041","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.3390\/cancers12113306","article-title":"Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial","volume":"12","author":"Arcadipane","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clcc.2021.09.006_bib0042","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajco.12768","article-title":"Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer","volume":"14","author":"Arcadipane","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0043","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0044","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00330-016-4337-z","article-title":"The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer","volume":"27","author":"Kochhar","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0045","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/bjs.4908","article-title":"Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer","volume":"92","author":"Renehan","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.clcc.2021.09.006_bib0046","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1046\/j.1365-2168.2002.02231.x","article-title":"Salvage abdominoperineal resection in anal epidermoid cancer","volume":"89","author":"Nilsson","year":"2002","journal-title":"Br J Surg"},{"key":"10.1016\/j.clcc.2021.09.006_bib0047","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.radonc.2018.06.007","article-title":"Determinants for local tumour control probability after radiotherapy of anal cancer","volume":"128","author":"Johnsson","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0048","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.radonc.2015.07.014","article-title":"A tumor control probability model for anal squamous cell carcinoma","volume":"116","author":"Muirhead","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0049","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/0284186X.2021.1918763","article-title":"Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer","volume":"60","author":"Sl\u00f8rdahl","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0050","unstructured":"ISRCTN. PLATO trial: personalising anal cancer radioTherapy dOse \u2013 incorporating ACT3, ACT4 and ACT5. Accessed 1.3.21 from: http:\/\/www.isrctn.com\/ISRCTN88455282."},{"key":"10.1016\/j.clcc.2021.09.006_bib0051","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00384-020-03687-8","article-title":"Outcome following local excision of T1 anal cancers-a systematic review","volume":"35","author":"Pedersen","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clcc.2021.09.006_bib0052","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/codi.14571","article-title":"Early stage anal margin cancer: towards evidence-based management","volume":"21","author":"Renehan","year":"2019","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.clcc.2021.09.006_bib0053","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clon.2018.11.034","article-title":"Is there a role for an 18f-fluorodeoxyglucose-derived biological boost in squamous cell anal cancer?","volume":"31","author":"Sabbagh","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clcc.2021.09.006_bib0054","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbcan.2017.05.001","article-title":"The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy","volume":"1868","author":"Martin","year":"2017","journal-title":"Biochimica et biophysica acta Reviews on cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2018.02.001","article-title":"Anal squamous cell carcinoma - State of the art management and future perspectives","volume":"65","author":"Martin","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2021.09.006_bib0056","first-page":"43","article-title":"RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial","volume":"23","author":"Martin","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0057","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/bjc.2016.398","article-title":"Biomarkers in anal cancer: from biological understanding to stratified treatment","volume":"116","author":"Jones","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0058","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0059","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8(+) and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clcc.2021.09.006_bib0060","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American joint committee on cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0061","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.20","article-title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53","volume":"112","author":"Meulendijks","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0062","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.28979","article-title":"Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy","volume":"136","author":"Rodel","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0063","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bjc.6602486","article-title":"Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy","volume":"92","author":"Charnley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0064","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/COC.0000000000000736","article-title":"Feasibility and outcome of routine use of concurrent chemoradiation in HIV-positive patients with squamous cell anal cancer","volume":"43","author":"Leiker","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clon.2016.12.010","article-title":"Are there HIV-specific differences for anal cancer patients treated with standard chemoradiotherapy in the era of combined antiretroviral therapy?","volume":"29","author":"Martin","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clcc.2021.09.006_bib0066","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/DCR.0000000000000057","article-title":"Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease","volume":"57","author":"Fraunholz","year":"2014","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.clcc.2021.09.006_bib0067","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0068","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40265-017-0792-3","article-title":"Pharmacotherapy of anal cancer","volume":"77","author":"Rogers","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.clcc.2021.09.006_bib0069","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11912-018-0698-6","article-title":"Systemic therapies for advanced squamous cell anal cancer","volume":"20","author":"Sclafani","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clcc.2021.09.006_bib0070","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0071","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0072","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2272","article-title":"LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy","volume":"31","author":"Rao","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0073","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0074","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-020-06841-1","article-title":"Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial","volume":"20","author":"Kim","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0075","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2008.11.021","article-title":"Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement","volume":"75","author":"Hodges","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0076","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2018.04.076","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clcc.2021.09.006_bib0077","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13014-020-01567-7","article-title":"Patterns of recurrence in anal cancer: a detailed analysis","volume":"15","author":"Nilsson","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0078","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1245\/s10434-007-9467-8","article-title":"Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis","volume":"14","author":"Pawlik","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0079","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.ejso.2017.09.006","article-title":"Long term outcome after resection of liver metastases from squamous cell carcinoma","volume":"43","author":"Omichi","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jso.25320","article-title":"Multimodality treatment of oligometastatic anal squamous cell carcinoma: a case series and literature review","volume":"119","author":"Sclafani","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0081","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.clcc.2021.09.006_bib0082","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/DCR.0000000000000827","article-title":"Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: a single-institution experience","volume":"60","author":"Evesque","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.clcc.2021.09.006_bib0083","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.amjsurg.2020.08.016","article-title":"Role of metastasectomy for liver metastasis in stage IV anal cancer","volume":"221","author":"Goldner","year":"2021","journal-title":"Am J Surg"},{"key":"10.1016\/j.clcc.2021.09.006_bib0084","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/S1470-2045(15)00292-2","article-title":"Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention","volume":"16","author":"Bernardi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0085","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.bjc.6605984","article-title":"Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review","volume":"103","author":"Lampejo","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0086","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1038\/bjc.2012.479","article-title":"EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?","volume":"107","author":"Paliga","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0087","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.radonc.2013.08.002","article-title":"p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy","volume":"109","author":"Gilbert","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0088","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/cncr.28055","article-title":"Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin","volume":"119","author":"Williams","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0089","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.radonc.2016.12.009","article-title":"Leukocytosis and neutrophilia predicts outcome in anal cancer","volume":"122","author":"Schernberg","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.radonc.2017.06.009","article-title":"External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation","volume":"124","author":"Schernberg","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0091","doi-asserted-by":"crossref","first-page":"O90","DOI":"10.1111\/codi.12467","article-title":"Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus","volume":"16","author":"Toh","year":"2014","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.clcc.2021.09.006_bib0092","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/cam4.3886","article-title":"Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study","volume":"10","author":"Truelsen","year":"2021","journal-title":"Cancer medicine"},{"key":"10.1016\/j.clcc.2021.09.006_bib0093","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.2147\/CMAR.S197349","article-title":"Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)","volume":"11","author":"Casadei-Gardini","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.clcc.2021.09.006_bib0094","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cancers13040671","article-title":"The prognostic value of the new combined hemo-eosinophil inflammation index (HEI Index): a multicenter analysis of anal cancer patients treated with concurrent chemo-radiation","volume":"13","author":"Rimini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clcc.2021.09.006_bib0095","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/1078-0432.CCR-18-0922","article-title":"Prognostic impact of residual HPV ctDNA detection after chemoradiotherapy for anal squamous cell carcinoma","volume":"24","author":"Cabel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2021.09.006_bib0096","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-18-2984","article-title":"Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the epitopes-HPV02 trial","volume":"25","author":"Bernard-Tessier","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2021.09.006_bib0097","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2020.06.045","article-title":"Measurement of circulating free DNA in squamous cell carcinoma of the anus and relation to risk factors and recurrence","volume":"150","author":"Lef\u00e8vre","year":"2020","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2021.09.006_bib0098","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.3390\/cancers13102451","article-title":"The clinical value of measuring circulating HPV DNA during chemo-radiotherapy in squamous cell carcinoma of the anus","volume":"13","author":"Lef\u00e8vre","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clcc.2021.09.006_bib0099","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/sj.bjc.6690567","article-title":"Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy","volume":"80","author":"Allal","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0100","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/0284186X.2013.770599","article-title":"Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors","volume":"52","author":"Bentzen","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0101","first-page":"3613","article-title":"Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy","volume":"23","author":"Sodergren","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0102","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.24906","article-title":"Long-term quality of life after radiotherapy for the treatment of anal cancer","volume":"116","author":"Das","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0103","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2013.05.037","article-title":"Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort","volume":"108","author":"Bentzen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0104","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12029-019-00233-w","article-title":"Sexual function, quality of life, and mood after radiation therapy in patients with anal cancer","volume":"51","author":"Yerramilli","year":"2020","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2468-1253(18)30264-4","article-title":"A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus","volume":"3","author":"Fish","year":"2018","journal-title":"The lancet Gastroenterology & hepatology"},{"key":"10.1016\/j.clcc.2021.09.006_bib0106","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2017.11.018","article-title":"Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer","volume":"126","author":"Sodergren","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0107","doi-asserted-by":"crossref","unstructured":"Basch E. The missing voice of patients in drug-safety reporting. 2010; 362: 865-9.","DOI":"10.1056\/NEJMp0911494"},{"key":"10.1016\/j.clcc.2021.09.006_bib0108","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.radonc.2018.06.006","article-title":"Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization","volume":"128","author":"Kronborg","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.09.006_bib0109","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","article-title":"Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative","volume":"51","author":"Bogaerts","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2021.09.006_bib0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2021.03.013","article-title":"Predicting outcomes in anal cancer patients using multi-centre data and distributed learning - A proof-of-concept study","volume":"159","author":"Choudhury","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282100092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282100092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:19Z","timestamp":1761520039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300282100092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S153300282100092X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2021.09.006","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2021.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}